Positive Social Impacts Related to Participation in an HIV Prevention Trial Involving People Who Inject Drugs

IRB. 2015 Jan-Feb;37(1):17-9.

Abstract

Although attention has focused on whether participants actually derive better medical outcomes in research, the social benefits experienced in research have not been systematically examined. At regular follow-up visits during a phase III randomized trial assessing the safety and efficacy of a long-term versus a short-term drug treatment intervention in decreasing HIV transmission and mortality conducted in China and Thailand, participants identified research-related negative and positive social impacts (PSIs). Open-ended PSI responses were coded using standard qualitative techniques. Among 1025 participants, only 4 reported a negative social impact; however, 77% reported at least one PSI over the 104 week follow-up period. Given the high prevalence of PSIs we observed, future research should embed assessments of negative and positive social impacts experienced by participants in research not only to ensure their well-being, but also to inform policy and conceptual work related to research ethics.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Buprenorphine / therapeutic use*
  • China
  • Clinical Trials, Phase III as Topic
  • Counseling
  • Female
  • HIV Infections / prevention & control*
  • Humans
  • Male
  • Naloxone / therapeutic use*
  • Narcotic Antagonists / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Research Design
  • Social Capital*
  • Substance Abuse, Intravenous / complications*
  • Substance Abuse, Intravenous / drug therapy*

Substances

  • Narcotic Antagonists
  • Naloxone
  • Buprenorphine